Clinical Trial Update: Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 Lung-MAP non-match trial evaluating ramucirumab plus pembrolizumab versus standard of care in stage IV or recurrent non-small cell lung cancer. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Zaltrap (ramucirumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2023-04-25